Tandon, R, Fleischhacker, WW. Comparative efficacy of antipsychotics in the treatment of schizophrenia: a critical assessment. Schizophr Res
2005; 79: 145–55.
Kane, JM, Eerdekens, M, Lindenmayer, JP, Keith, SJ, Lesem, M, Karcher, K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry
2003; 160: 1125–32.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Chue, P, Eerdekens, M, Augustyns, I, Lachaux, B, Molcan, P, Eriksson, L, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol
2005; 15: 111–7.
Turner, M, Eerdekens, E, Jacko, M, Eerdekens, M. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol
2004; 19: 241–9.
Fleischhacker, WW, Eerdekens, M, Karcher, K, Remington, G, Llorca, PM, Chrzanowski, W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry
2003; 64: 1250–7.
Lasser, RA, Bossie, CA, Gharabawi, GM, Turner, M. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry
2004; 19: 219–25.
Van Os, J, Bossie, CA, Lasser, RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol
2004; 19: 229–32.
Lasser, RA, Bossie, CA, Gharabawi, GM, Baldessarini, RJ. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol
2005; 8: 427–38.
Lasser, RA, Bossie, CA, Zhu, Y, Gharabawi, G, Eerdekens, M, Davidson, M. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry
2004; 19: 898–905.
Lasser, R, Bossie, CA, Gharabawi, G, Eerdekens, M, Nasrallah, HA. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord
2004; 83: 263–75.
Gharabawi, GM, Bossie, CA, Zhu, Y, Mao, L, Lasser, RA. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res
2005; 77: 129–39.
Leal, A, Rosillon, D, Mehnert, A, Jarema, M, Remington, G. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf
2004; 13: 811–6.
Lasser, RA, Bossie, CA, Zhu, Y, Locklear, JC, Kane, JM. Long-acting risperidone in young adults with early schizophrenia or schizoaffective illness. Ann Clin Psychiatry
2007; 19: 65–71.
Andreasen, NC, Carpenter, WT, Kane, JM, Lasser, RA, Marder, SR, Weinberger, DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry
2005; 162: 441–9.
Van Os, J, Burns, T, Cavallaio, R, Leucht, S, Peuskens, J, Helldin, L, et al. Standardized remission criteria in schizophrenia. Acta Psychiatr Scand
2006; 113: 91–5.
Lasser, RA, Bossie, CA, Gharabawi, GM, Kane, JM. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res
2005; 77: 215–27.
Nasrallah, HA, Duchesne, I, Mehnert, A, Janagap, C, Eerdekens, M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. J Clin Psychiatry
2004; 65: 531–6.
Fleischhacker, WW, Rabinowitz, J, Kemmler, G, Eerdekens, M, Mehnert, A. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry
2005; 187: 131–6.
Awad, AG, Hogan, TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand Suppl
1994; 380: 27–32.
Lindenmayer, JP, Jarboe, K, Bossie, CA, Zhu, Y, Mehnert, A, Lasser, RA. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharm
2005; 20: 213–21.
Bloch, Y, Mendlovic, S, Strupinsky, S, Altshuler, A, Fennig, S, Ratzoni, G. Injections of depot antipsychotic medications in patients suffering from schizophrenia: do they hurt?
J Clin Psychiatry
2001; 62: 855–9.
Lindenmayer, JP, Eerdekens, E, Berry, SA, Eerdekens, M. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry
2004; 65: 1084–9.
Lindenmayer, JP, Khan, A, Eerdekens, M, Van Hove, I, Kushner, S. Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. Eur Neuropsychopharm
2007; 17: 138–44.
Bai, YM, Chen, TT, Chen, JY, Chang, WH, Wu, B, Hung, CH, et al. Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J Clin Psychiatry
2007; 68: 1218–25.
Simpson, GM, Mahmoud, RA, Lasser, RA, Kujawa, M, Bossie, CA, Turkoz, I, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry
2006; 67: 1194–203.
Gharabawi, G, Bossie, C, Turkos, I, Kujawa, M, Mahmoud, R, Simpson, G. The impact of insight on functioning in patients with schizophrenia or schizoaffective disorder receiving risperidone long-acting injectable. J Nerv Ment Dis
2007; 195: 976–82.
Keks, NA, Ingham, M, Khan, A, Karcher, K. Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder. Br J Psychiatry
2007; 191: 131–9.
Möller, HJ, Llorca, PM, Sacchetti, E, Martin, SD, Medori, R, Parellada, E. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol
2005; 20: 121–30.
Supplement: Progress in modern psychopharmacology. Clinical experience with risperidone long-acting injectable in schizophrenia and schizoaffective disorders. Journal Psychopharm
2005; 19 (5 suppl): 1–40.
Llorca, PM, Sacchetti, E, Lloyd, K, Kissling, W, Medori, R. Long-term remission in schizophrenia and related psychoses with long-acting risperidone: results obtained in an open-label study with an observation period of 18 months. Int J Clin Pharmacol Therap
2008; 46: 14–22.
Kissling, W, Glue, P, Medori, R, Simpson, S. Long-term safety and efficacy of long-acting risperidone in elderly psychotic patients. Hum Psychopharmacol Clin Exp
2007; 22: 505–13.
Gharabawi, GM, Gearhart, NC, Lasser, RA, Mahmoud, RA, Zhu, Y, Mannaert, E, et al. Maintenance therapy with once-monthly administration of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder: a pilot study of an extended dosing interval. Ann Gen Psychiatry
2007; 6: 3.
Emsley, R, Medori, R, Koen, L, Oosthuizen, PP, Niehaus, DJH, Rabinowitz, J. Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis. J Clin Psychopharmacol
2008; 25: 210–13.
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IPM, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet
2008; 371: 1085–97.
Strassnig, M, Miewald, J, Keshawan, M. Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis. Schizophr Res
2007; 93: 90–8.
Taylor, DM, Young, CL, Mace, S, Patel, MX. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry
2004; 65: 1076–83.
Patel, MX, Young, C, Samele, C, Taylor, DM, David, AS. Prognostic indicators for early discontinuation of risperidone long-acting injection. Int Clin Psychopharmacol
2004; 19: 233–9.
Taylor, DM, Young, C, Patel, MX. Prospective 6-month follow-up of patients prescribed risperidone long acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol
2005; 9: 1–10.
Niaz, OS, Haddad, PM. Thirty-five months experience of risperidone long-acting injection in a UK psychiatric service including a mirror-image analysis of in-patient care. Acta Psychiatr Scand
2007; 116: 36–46.
Taylor, M, Currie, A, Lloyd, K, Price, M, Peperell, K. Impact of risperidone long acting injection on resource utilization in psychiatric secondary care. J Psychopharmacol
2008; 22: 128–31.
Olfson, M, Marcus, SC, Ascher-Svanum, H. Treatment of schizophrenia with long-acting fluphenazine, haloperidol or risperidone. Schizophr Bull
2007; 33: 1379–87.
Castberg, I, Spigset, O. Serum Concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone. Ther Drug Monit
2005; 27: 103–6.
Nesvag, R, Tanum, L. Therapeutic drug monitoring of patients on risperidone depot. Nord J Psychiatry
2005; 59: 51–5.
Haring, C, Meise, U, Humpel, C, Saria, A, Fleischhacker, WW, Hinterhuber, H. Dose-related plasma levels on clozapine: influence of smoking behavior, sex and age. Psychopharmacology
1989; 99: 38–40.
Eerdekens, M, Van Hove, I, Remmerie, B, Mannaert, E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res
2004; 70: 91–100.
Gefvert, O, Eriksson, B, Persson, P, Helldin, L, Björner, A, Mannaert, E, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta TM) in patients with schizophrenia. Int J Neuropsychopharm
2005; 8: 27–36.
Uchida, H, Mamo, DC, Kapur, S, Labelle, A, Shammi, C, Mannaert, EJL, et al. Monthly administration of long-acting injectable risperidone and striatal dopamine D2 receptor occupancy for the management of schizophrenia. J Clin Psychiatry
2008; 69: 1281–6.
Surguladze, SA, Chu, EM, Evans, A, Anilkumar, APP, Patel, MX, Timehin, C, et al. The effect of long-acting risperidone on working memory in schizophrenia. J Clin Psychopharmacol
2007; 27: 560–70.
Rubio, G, Martinez, I, Ponce, G, Jimenez-Arriero, MA, Lopez-Munoz, F, Alamo, C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry
2006; 51: 531–9.
Committee for Medicinal Products for Human Use. Summary of Positive Opinion for Zypadhera 2008: . CHMP, 2008.
Lauriello, J, Lambert, T, Andersen, S, Lin, D, Taylor, CC, McDonnell, D. An 8-week, double-blind, randomized, placebo-controlled study of olanzapine long-acting injection in acutely ill patients with schizophrenia. J Clin Psychiatry
2008; 69: 790–9.
Detke, H, McDonnell, D, Kane, J, Naber, D, Sethuraman, G, Lin, D. Olanzapine long-acting injection for the maintenance treatment of schizophrenia: a 24-week, randomized, double-blind trial. Schizophr Res
2008; 102 (suppl 2): 1–279.
McDonnell, D, Sorsaburu, D, Brunner, E, Detke, H, Andersen, S, Bergstrom, R, et al. Post-injection delirium/sedation syndrome observed with olanzapine long-acting injection: review of the first 25 events. Eur Neuropsychopharm
2008; 18 (suppl 4): S437–8.
Mamo, D, Kapur, S, Keshawan, M, Laruelle, M, Taylor, CC, Kothare, PA, et al. D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography: an open-label study in patients with schizophrenia. Neuropsychopharmacology
2008; 33: 298–304.
Kramer, M, Litman, R, Hough, D, Lane, R, Lim, P, Lin, Y, et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharm
Hough, D, Gopal, S, Vijapurkar, U, Lim, P, Morozova, M, Eerdekens, M. Paliperidone palmitate, an injectable antipsychotic in prevention of symptom recurrence in patients with schizophrenia: a randomized, double blind, placebo-controlled study. Biol Psychiatry
2008; 63 (suppl 1): 285S.
Nasrallah, HA, Gopal, S, Quiroz, JA, Gassmann-Mayer, C, Lim, P, Eerdekens, M, et al. Efficacy and safety of three doses of paliperidone palmitate, an investigational long-acting injectable antipsychotic in schizophrenia. In American Psychiatric Association 2008 Annual Meeting: New Research Abstracts: 176
. APA, 2008 (http://www.psych.org/am2008newresearch).
Gopal, S, Lindenmayer, JP, Hough, D, Melkote, R, Lim, P, Eerdekens, M. Safety and tolerability of the investigational antipsychotic paliperidone palmitate injected in the deltoid or gluteus muscle in patients with schizophrenia. Biol Psychiatry
2008; 63 (suppl 1): 285S.
Hill, CL, Phadke, D, Boyce, KM. Four-week iloperidone depot injectable: safety and pharmacokinetic profile in patients with schizophrenia and schizoaffective disorder. In American Psychiatric Association 2008 Annual Meeting: New Research Abstracts 169
. APA, 2008 (http://www.psych.org/am2008newresearch).